Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 944-550-8 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Description of key information
No data is available for the target substance.
In a study examining fertility and embryofetal development in rats dosed with 0, 100U/kg human insulin dosed twice daily by s.c. administration (corresponding to 0; 7.60 mg/kg/day) the males were dosed from 4 weeks before mating and females from 2 weeks before mating until day 15 of pregnancy. Reduced blood glucose levels were observed in relation to the dosing and one male rat died presumably due to severe hypoglycaemia. No effects on mating performance or pregnancy rate was observed, but slightly increased pre-and postimplanation losses was seen and a slight increase of foetuses with small orbital sockets was noted . Slightly reduced sperm count and slight histopathological changes in testes were found in males. The findings in the study was considered most likely to be induced by hypoglycaemia.A study examining peri- and postnatal toxicity toxicity study was conducted with human insulin in female rats using dose levels of 0, 100U/kg dosed twice daily by s.c. administration (corresponding to 0; 7.60 mg/kg/day) from D6 of gestation to D20 after parturation. The administration of human insulin did not result in any effects on fertility or development. Hypoglycaemia was observed in the adult animals including a few lethal outcomes.
A developmental toxicity study in rabbits dosed with 0; 0.5; 1.5; 5 U/kg/ twice daily from day 6 to day 18 of pregnancy by s.c. injection (corresponding to 0; 0.04; 0.11; 0.38 mg/kg/d) resulted in an increase in early embryonic death and reduction of litter size at highest dose level and at all dose levels in a higher proportion of skeletal abnormalities. Blood glucose levels were affected in a dose-related manner and effects in relation to fertility and development were suggested to be secondary effects of lowered maternal blood glucose levels.
The findings from these studies are considered relevant for Insulin DesB30 as well as this substance also bind 100% to the insulin receptor and thus has the potential to induce a hypoglycaemic response. The data does not indicate any need for CLP-classification for fertility or development as the effects seen is primarily considered secondary to maternal toxicity. In addition, the dosing has been performed with s.c. administration, which make interpretation for more relevant exposure routes in terms of classification very difficult.
Link to relevant study records
- Endpoint:
- screening for reproductive / developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study without detailed documentation
- Justification for type of information:
- The present study, NDA report No. T-20, study nr. 940303, is described in a summary study report on Insulin aspart is based on GLP guideline studies prepared by Novo Nordisk. The summarised studies were performed as part of the non-clinical toxicity test regime for authorisation of Insulin aspart as human medicine and the studies are therefore in compliance with the guidelines for authorisation of human medicine.
The study is a fertility and Embryofoetal developmental toxicity study in the Rat performed in accordance with ICH test guidelines 4.1.1 + 4.1.3 (comparable to OECD 421/422). - Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Deviations:
- yes
- Remarks:
- Subcutaneous administration used instead of oral administration.
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 421 (Reproduction / Developmental Toxicity Screening Test)
- Deviations:
- yes
- Remarks:
- Subcutaneous administration used instead of oral administration.
- GLP compliance:
- yes
- Limit test:
- yes
- Specific details on test material used for the study:
- Study performed with the active pharmaceutical ingredient Human Insulin (Actrapid)
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Route of administration:
- subcutaneous
- Vehicle:
- not specified
- Details on exposure:
- NA
- Details on mating procedure:
- NA
- Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- Female rats were treated for 2 weeks prior mating and dosing continued up to and including day 15 of pregnancy (total of 29 days).
Male rats were treated for 4 weeks prior mating and dosing continued up to day 20 of pregnancy (total of 48 days). - Frequency of treatment:
- Twice daily. S.C administration.
- Details on study schedule:
- NA
- Dose / conc.:
- 0 mg/kg bw/day (actual dose received)
- Remarks:
- Vehicle control group
- Dose / conc.:
- 7.6 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 24
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Based on results of a previous study
the daily dose level was distrubuted into subcutaneous injections twice daily - Positive control:
- no
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: not specified
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: NA
BODY WEIGHT: Yes
- Time schedule for examinations: NA
-Other:
- Food and water consumption was recorded, although not a feeding or water study. - Sperm parameters (parental animals):
- Parameters examined in [all] male rats:
[testis weight, sperm count, sperm motility, sperm morphology] - Litter observations:
- STANDARDISATION OF LITTERS
- not specified
PARAMETERS EXAMINED
The following parameters were examined in [F1] offspring:
[number and distrubution, stillbirths, live births, postnatal mortality, presence of gross anomalies, weight gain].
Live young were examined externally and weighted. Half the fetuses were examined for viceral abnormalities and half were examined for skeletal abnormalities.
GROSS EXAMINATION OF DEAD PUPS:
[ yes, for external and internal abnormalities] - Postmortem examinations (parental animals):
- SACRIFICE
- Female and Male animals killed at Day 20 of pregnancy.
GROSS NECROPSY
- Yes, not specified
HISTOPATHOLOGY / ORGAN WEIGHTS
- Congenital abnormalities and number of corpora lutea (maternal animals)
- male reproductive system including, testes and sperm (parental animals) - Postmortem examinations (offspring):
- SACRIFICE
GROSS NECROPSY
- Gross necropsy consisted of [external and internal examinations including the cervical, thoracic, and abdominal viscera, Skeletal morphology and Orbital socklet morphology.]
HISTOPATHOLOGY / ORGAN WEIGTHS
The tissues indicated in Table [#] were prepared for microscopic examination and weighed, respectively. - Statistics:
- not specified
- Clinical signs:
- no effects observed
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- Death of one male animal 7.60 mg/kg/day. This effect was most likely related to the pharmacological action of human insulin (Actrapid) causing severe hypoglycemia.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Weight gain (and increased food and water intake) observed.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- A dosage related increase in food and water intake was seen, although the study is not a feeding study.
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Plasma glucose was reduced from about 10 mmol/l to 4-6 mmol/l at one hour after dosing with 7.60 mg/kg/day, rate of recovery showing some dosage-dependency.
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not specified
- Histopathological findings: non-neoplastic:
- not specified
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- not specified
- Reproductive function: oestrous cycle:
- effects observed, treatment-related
- Description (incidence and severity):
- Slightly reduced pre- and post implantation losses were observed at 7.60 mg/kg/day.
- Reproductive function: sperm measures:
- effects observed, treatment-related
- Description (incidence and severity):
- Slightly reduced sperm counts and motility and focal seminiferous epithelial atrophy with vacuolation of Sertoli cells in testes at 7.60 mg/kg/day.
- Reproductive performance:
- no effects observed
- Key result
- Dose descriptor:
- LOAEL
- Effect level:
- ca. 7.6 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- mortality
- reproductive function (oestrous cycle)
- reproductive function (sperm measures)
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 7.6 mg/kg bw/day (actual dose received)
- System:
- male reproductive system
- Organ:
- testes
- Treatment related:
- yes
- Dose response relationship:
- not specified
- Relevant for humans:
- not specified
- Clinical signs:
- not examined
- Dermal irritation (if dermal study):
- not examined
- Mortality / viability:
- not examined
- Body weight and weight changes:
- not examined
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Detailed foetal examination revealed a slight dosage related increase in the incidence of fetuses with absent or small orbital sockets at 7.60 mg/kg/day.
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Sexual maturation:
- not examined
- Organ weight findings including organ / body weight ratios:
- not specified
- Gross pathological findings:
- no effects observed
- Histopathological findings:
- not specified
- Other effects:
- not specified
- Behaviour (functional findings):
- not examined
- Developmental immunotoxicity:
- not examined
- Key result
- Dose descriptor:
- LOAEL
- Generation:
- F1
- Effect level:
- ca. 7.6 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- not specified
- Basis for effect level:
- ophthalmological examination
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 7.6 mg/kg bw/day (actual dose received)
- System:
- other:
- Organ:
- other: ophthalmological abnormalities
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- not specified
- Key result
- Reproductive effects observed:
- yes
- Lowest effective dose / conc.:
- 7.6 mg/kg bw/day (actual dose received)
- Treatment related:
- yes
- Relation to other toxic effects:
- reproductive effects in the absence of other toxic effects
- Dose response relationship:
- yes
- Relevant for humans:
- not specified
- Conclusions:
- A fertility and embryofoetal developmental toxicity study in the Rat performed in accordance with ICH test guidelines 4.1.1 + 4.1.3 (comparable to OECD 421/422). 24 male and 24 female rats were daily dosed subcutaneously with Human Insulin (0, 7.6 mg/kg/ bw/day) for 4-7 weeks. Mortality was observed in one male at highest dose level, an effect of the pharmacological action of severe insulin-induced hypoglycemia. However, terminal studies on male rats also revealed a slightly reduced sperm count and and motility and histopathology showed focal seminiferous epithelial atrophy with vacuolation of Sertoli cells in testes of male rats dosed 7.6 mg/kg/day. Detailed foetal examination revealed a slight dosage related increase in fetuses with absent or small orbital socket. No other toxicity was observed in parental or foetal animals.
- Executive summary:
A fertility and embryofoetal developmental toxicity study in the Rat performed in accordance with ICH test guidelines 4.1.1 + 4.1.3 (comparable to OECD 421/422). 24 male and 24 female rats were daily dosed subcutaneously with Human Insulin (0, 7.6 mg/kg/ bw/day) for 4-7 weeks. Mortality was observed in one male at highest dose level, an effect of the pharmacological action of severe insulin-induced hypoglycemia. However, terminal studies on male rats also revealed a slightly reduced sperm count and and motility and histopathology showed focal seminiferous epithelial atrophy with vacuolation of Sertoli cells in testes of male rats dosed 7.6 mg/kg/day. Detailed foetal examination revealed a slight dosage related increase in fetuses with absent or small orbital socket. No other toxicity was observed in parental or foetal animals.
- Endpoint:
- screening for reproductive / developmental toxicity
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Justification for type of information:
- No data is available for the target substance.
In a study examining fertility and embryofoetal development in rats dosed with 0, 100U/kg human insulin dosed twice daily by s.c. administration (corresponding to 0; 7.60 mg/kg/day) the males were dosed from 4 weeks before mating and females from 2 weeks before mating untill day 15 of pregnancy. Reduced blood glucose levels were observed in relation to the dosing and one male rat died presumably due to severe hypoglycaemia. No effects on mating performance or pregnancy rate was observed, but slightly increased pre-and postimplantation losses was seen and a slight increase of foetuses with small orbital sockets was noted . Slightly reduced sperm count and slight histopathological changes in testes were found in males. The findings in the study was considered most likely to be induced by hypoglycaemia.
A two-generation reproductive toxicity study was conducted with human insulin in rats using dose levels of 0, 100U/kg dosed twice daily by s.c. administration (corresponding to 0; 7.60 mg/kg/day). The administration of human insulin did not result in any effects on fertility or development. Hypoglycaemia was observed in the adult animals. Maternal toxicity was observed and was considered to be linked to the induction of hypoglycaemia and eight of 28 females died on day 20 to 23 of gestation.
A developmental toxicity study in rabbits dosed with 0; 0.5; 1.5; 5 U/kg/ twice daily from day 6 to day 18 of pregnancy by s.c. injection (corresponding to 0; 0.04; 0.11; 0.38 mg/kg/d) resulted in an increase in early embryonic death and reduction of litter size at highest dose level and at all dose levels in a higher proportion of skeletal abnormalities. Blood glucose levels were affected in a dose-related manner and effects in relation to fertility and development were suggested to be secondary effects of lowered maternal blood glucose levels.
The findings from these studies are considered relevant for Insulin DesB30 as well as this substance also bind 100% to the insulin receptor and thus has the potential to induce a hypoglycaemic response. The data does not indicate any need for CLP-classification for fertility or development as the effects seen is primarily considered secondary to maternal toxicity. Also, the dosing has been performed with s.c. administration which make interpretation for more relevant exposure routes in terms of classification very difficult. - Reason / purpose for cross-reference:
- read-across source
- Key result
- Dose descriptor:
- LOAEL
- Effect level:
- 7.6 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- mortality
- reproductive function (oestrous cycle)
- reproductive function (sperm measures)
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 7.6 mg/kg bw/day (actual dose received)
- System:
- male reproductive system
- Organ:
- testes
- Treatment related:
- yes
- Dose response relationship:
- not specified
- Relevant for humans:
- not specified
- Key result
- Dose descriptor:
- LOAEL
- Effect level:
- 7.6 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- mortality
- reproductive function (oestrous cycle)
- reproductive function (sperm measures)
- other: (female only) pre and post implant losses
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 7.6 mg/kg bw/day (actual dose received)
- System:
- male reproductive system
- Organ:
- testes
- Treatment related:
- yes
- Dose response relationship:
- not specified
- Relevant for humans:
- not specified
- Key result
- Dose descriptor:
- LOAEL
- Generation:
- F1
- Effect level:
- 7.6 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- not specified
- Basis for effect level:
- ophthalmological examination
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 7.6 mg/kg bw/day (actual dose received)
- System:
- other:
- Organ:
- other: ophthalmological abnormalities
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- not specified
- Key result
- Reproductive effects observed:
- yes
- Lowest effective dose / conc.:
- 7.6 mg/kg bw/day (actual dose received)
- Treatment related:
- yes
- Relation to other toxic effects:
- reproductive effects in the absence of other toxic effects
- Dose response relationship:
- yes
- Relevant for humans:
- not specified
- Conclusions:
- No data is available for the target substance. Data on fertility and development is only available on the active pharmaceutical ingredient (API) Human Insulin in connection with subcutaneous injections. This route of exposure is considered relevant since systemic effects are observed. The effects seen in relation to mortality in male rats is an effect of the pharmacological action of severe insulin-induced hypoglycemia. In addition the reduction in sperm count and motility and focal seminiferous epithelial atrophy with vacuolation of Sertoli cells in testes of male rats dosed 7.6 mg/kg/day is considered as a consequence of the hypoglycaemic mode of action of the substance and as secondary effects of the maternal toxicity. Detailed foetal examination revealed a slight dosage related increase in fetuses with absent or small orbital socket. No other toxicity was observed in parental or foetal animals.
Insulin DesB30 is able to bind to the insulin receptor with equal affinity as Human Insulin, thus it is assumed to induce the same hypoglycemia-related effects.
Therefore, the effects seen from subcutaneous injection of Human Insulin is likely to occur in relation to oral, dermal or inhalational exposure to Insulin DesB30. - Executive summary:
Data on fertility and development is only available on the active pharmaceutical ingredient (API) Human Insulin in connection with subcutaneous injections. This route of exposure is considered relevant since systemic effects are observed. The effects seen in relation to mortality in male rats is an effect of the pharmacological action of severe insulin-induced hypoglycemia. In addition the reduction in sperm count and motility and focal seminiferous epithelial atrophy with vacuolation of Sertoli cells in testes of male rats dosed 7.6 mg/kg/day is considered as a consequence of the hypoglycaemic mode of action of the substance and as secondary effects of the maternal toxicity. Detailed foetal examination revealed a slight dosage related increase in fetuses with absent or small orbital socket. No other toxicity was observed in parental or foetal animals.
Insulin DesB30 is able to bind to the insulin receptor with equal affinity as Human Insulin, thus it is assumed to induce the same hypoglycemia-related effects.
Therefore, the effects seen from subcutaneous injection of Human Insulin is likely to occur in relation to oral, dermal or inhalational exposure to Insulin DesB30.
Referenceopen allclose all
Effects on developmental toxicity
Description of key information
Data on fertility and development is only available on the active pharmaceutical ingredient insulin aspart in connection with subcutaneous injections. The effects seen in relation to maternal toxicity, fertility and development are overall considered as a consequence of the hypoglycaemic mode of action of the substance and as secondary effects of the maternal toxicity.
Justification for classification or non-classification
The findings from the the studies with human insulin are considered relevant for Insulin DesB30 as well as this substance also bind 100% to the insulin receptor and thus has the potential to induce a hypoglycaemic response. However, the data does not indicate any need for CLP-classification for fertility or development as the effects seen is primarily considered secondary to maternal toxicity. In addition, the dosing has been performed with s.c. administration, which make interpretation for more relevant exposure routes in terms of classification very difficult.
Based on weight of evidence Insulin DesB30 is not to be classified for reproductive toxicity according to the CLP-criteria.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.